GlobeNewsWire
08 Oct 2026, 05:00 UTC · 3h ago
Impact · against what's priced in
The completion of Phase 1 for Neurosterix's NTX-253 is a positive clinical milestone that advances the asset toward Phase 2. This provides a valuation step-up for Addex through its 20% equity stake, supported by a sufficient capital base from a $65 million Series A.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
Neurosterix has completed Phase 1 clinical studies of NTX-253 for schizophrenia and plans to advance to Phase 2.
Newannouncement dated October 8, 2026
So whatPhase 2 transition typically triggers a step-up in valuation for the 20% stake held by Addex.
More positive than 78% of claims this week
Addex Therapeutics holds a 20% equity interest in Neurosterix, which raised $65 million in Series A financing.
Continue reading
5 related stories
Neurosterix has successfully completed Phase 1 studies for NTX-253 and is moving into Phase 2, which typically increases the value of Addex's 20% equity stake.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inmentions spin-out occurred in April 2024
So whatThe $65M capital base suggests sufficient runway for early Phase 2 without immediate further dilution.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 63% of ticker scores this week
The company's spin-out, Neurosterix, successfully completed Phase 1 studies and is advancing a schizophrenia treatment to Phase 2.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
19h ago
—
ADXN hasn't traded since this ran. Last close $3.13 (Oct 7); the reaction starts at the next open.
ADXN chart →
